The course of pregnancy and childbirth in women with iron deficiency anemia treated with iron (II) sulfate and not treated

Introduction. Due to the plasma volume expansion prevailing over the increase in red blood cell production, as well as inadequate dietary intake with underlying physiologically increased iron requirements, pregnant women tend to suffer from iron deficiency and anaemia. Aim. To evaluate the efficacy of Tardyferon (depot iron (II) sulphate 80 mg) in pregnant women with anaemia in reducing adverse perinatal outcomes. Materials and methods. To conduct the retrospective chart review of pregnant women of Stavropol Krai, the patients were divided into 2 groups: Group 1 (n = 70) – the treatment group, which included pregnant women who were diagnosed with IDA in the 1st, 2nd or 3rd trimesters and who received antianemic therapy, and Group 2 (n = 30) – pregnant women with IDA (diagnosed in the 3rd trimester) who did not use any iron supplements. Results. In Group I, haemoglobin levels identified at the time of detection of anaemia ranged from 91 to 109 g/l (103.1 ± 4.5), red blood cell counts from 2.7 to 4.1 × 109/l (3.5 ± 0.3), and hematocrit levels from 26 to 37 (32.9 ± 1.8). Once the diagnosis of anaemia had been established, pregnant women were prescribed with Tardiferon 80 mg twice a day, which they administered on a regular basis until delivery and continued using during the postpartum period. In Group 2, patients did not receive any iron supplements and showed a gradual decrease in haemoglobin levels by an average of 5.6 g/l. Pregnant women receiving Tardyferon prolonged-release tablets from the date when anaemia was diagnosed showed an increase in clinical blood test values. Conclusions. In pregnant women with anaemia, iron therapy normalizes haematological parameters, which leads to improved tissue oxygen supply and a favourable clinical effect.